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A B S T R A C T
Background: Cardiogoniometry (CGM), a spatiotemporal electrocardiologic method may be useful as a
cardiovascular diagnostic tool. Increased incidence of coronary artery or myocardial involvement and
defects in automatic setting of heart activity have been reported in psoriasis which could be related to
the presence of systemic inﬂammation. Cardiogoniometry and the related parameters have been used in
this study as a diagnostic technique in psoriasis patients.
Methods: Thirty patients with psoriasis and 30 healthy, age and sex-matched individuals with no history
of cardiovascular diseases or traditional coronary risk factors were enrolled. Duration and severity of the
disease, using psoriasis severity and area index (PASI) score were recorded. Electrocardiography and
cardiogoniometry were performed. Heart rate, QT interval and QT dispersion (QTD) were measured.
SDNN (standard deviation of normal R-R interval) and myocardial ischemia score were determined by
cardiogoniometry.
Results: There was signiﬁcant difference between the psoriasis patients and the controls in terms of
heart rate (76.37  14.41 vs 72.53  9.684, p = 0.02), myocardial ischemia score (1.53  2.63 vs
0.46  0.73, p = 0.037), corrected QT interval (392.64  26.00 vs 377.26  22.34, p = 0.017) and QTD
(32.00  17.88 vs 6.67  15.16, p < 0.001). No statistically signiﬁcant difference was found in SDNN
(36.37  21.01 vs 26.90  14.88, p = .29). There were moderate correlation between PASI and SDNN
(r = 0.427, p = 0.009), heart rate (r = 0.427, p = .009) and score (r = 0.481, p = .004).
Conclusion: Abnormalities in resting ECG and CGM and their correlation with disease severity raises
concerns about the need for cardiovascular follow-ups of psoriatic patients, especially those with severe
disease.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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 Cardiologic examination is an important work up in psoriatic
patients especially cases with severe skin involvement. There are
no data regarding cardiogoniometry in psoriasis patients. CGM is
a method, which could provide additive data using SDNN (as a
marker for heart rate variability) and also myocardial ischemia
score.
1. Introduction
Psoriasis is a common T cell mediated inﬂammatory and
chronic disease affecting almost 1–3% of the human population.1ry in psoriatic patients and its comparison with a control group,
 India. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Position of electrodes. For data recording only four thoracic electrodes are
required and additional ground electrode also need. Green electrode is located
in 5th intercostal space. Anterior–posterior  (AP) chest diameter is determined
and white electrode located just opposite side of green lead on posterior
side. The distance of yellow and red electrodes is as the same of AP chest
diameter.
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differentiation in the epidermis, vascular changes, and lympho-
cytic inﬁltration.
Although best known for its dermatologic manifestations,
psoriasis may also accompany several other important morbid-
ities, including: arthritis, cancer, Crohn’s disease, ulcerative colitis,
non-alcoholic steatohepatitis, diabetes, depression, and cardio-
vascular abnormalities.2,3
Systemic inﬂammation in psoriasis is associated with many
cardiovascular unfavorable changes including: endothelial dys-
function, hypertension, platelet adhesion, and heart rate variabili-
ty.4,5 In a study by Ludwig et al. on psoriatic patients, increased risk
of myocardial infarction was found even after controlling for
coronary risk factors. This was more evident in those with severe
diseases.6
Patients with psoriasis have a shorter life expectancy, ascribed
to be due to cardiovascular abnormalities in most cases.7
Considering these data, it seems to be prudent to diagnose earlier
such cardiovascular abnormalities and manage them properly for
improving the survival in Psoriasis.
Cardiogoniometry (CGM) is a spatio-temporal orthogonal-lead
method using multiple electrodes and an automated diagnostic
algorithm to analyze a 12 s vectorcardiographic recording in the
resting patient. It detects variables that are helpful in identifying
ischemic heart disease or predicting heart rate variability, being
performed under resting conditions.8
There are no data regarding cardiogoniometry in psoriasis
patients. The aim of this study was to use ECG and CGM parameters
as indicators of cardiovascular abnormalities in psoriatic patients
and compare them with normal population.
2. Methods
Thirty patients, clinically diagnosed as psoriasis vulgaris by an
academic dermatologist, were involved in this cross-sectional
study from 2014 to 2015. They were selected consecutively from
the patients visiting the dermatologic clinic (Imam Reza Hospital).
The included patients did not have any clinical signs or symptoms
of cardiac problems, history of heart diseases, neurologic events or
conventional risk factors for atherosclerosis (hypertension, hyper-
lipidaemia, diabetes mellitus or cigarette smoking) or medications
including beta blocker, systemic steroids or anticoagulants. Thirty
healthy volunteer subjects were also enrolled. They were the
colleagues or family members of the study author or psoriasis
patients and did not have the clinical evidence of cardiac or
systemic disorders. Having similar age range and sex ratio to the
psoriatic group was considered while selecting the controls.
Psoriasis area and severity index (PASI) was used to assess
psoriasis severity.9
This study was carried out in accordance with the code of ethics
of the world medical association (declaration of Helsinki) for
experiments involving humans and obtained the approval of
research ethics committee of the Mashhad University of Medical
Sciences. The informed written consent was obtained from each
participant.
Both psoriasis and control groups underwent electrocardiogra-
phy and cardiogoniometry.
2.1. Cardiogoniometry (CGM)
The study data were collected by a commercial CGM device
(Cardiologic Explorer, Enverdis GmbH Medical Solutions,
Germany; Model E12K34). Four electrodes are placed at four
points on the patient’s thorax as follows (Fig. 1): Electrode 1, at
point V4 of Wilson (5th intercostal space in the mid-clavicular
line); 2, at point V8 of Wilson (5th intercostal space in the scapularPlease cite this article in press as: Poorzand H, et al. Cardiogoniomet
Indian Heart J. (2016), http://dx.doi.org/10.1016/j.ihj.2016.05.019line); 3, located perpendicularly above electrode 1 at 0.7 times the
distance between electrode 1 and 2; Electrode 4, to the right of
electrode 3 at the same distance as between points 1 and
3. Vectorial addition of the three potentials between pairs of these
electrodes results in a vector that describes the electric ﬁeld in each
plane (X, Y, Z).
During the recording, the patients lay in a supine position and
were asked to hold their breath for 12–15 s after normal
expiration. If this was not possible, they were asked to perform
shallow breathing and keep their thoracic excursions to a
minimum.
Cardiogoniometry uses different parameters compiled into
speciﬁc sets based on gender and conduction characteristics.
Analysis of all parameters is fully automated. Myocardial ischemia
score is expressed as values 0 (Figs. 2 and 3). Another parameter,
deﬁned as standard deviation of normal R-R interval (SDNN), is
used analogs to the extent of heart rate variability.
The CGM results were collected by an independent investigator
blinded to all patient data.
2.2. Twelve-lead electrocardiography
The resting 12-lead ECG (Cardisuny C120, Fukuda, Japan) was
recorded after the CGM. All ECGs were analyzed by one
independent investigator blinded to all patient data. The QT
interval was measured from the onset of the QRS complex to the
end of the T wave.
Due to the differences in QT interval in the different leads, the
maximum QT interval, measured manually, was used in each case.
Corrected QT interval was measured using this formula10:
QTc ¼ QT þ 1:75ðHR60Þ
QT dispersion was deﬁned as maximum difference in QT
interval considering all leads.ry in psoriatic patients and its comparison with a control group,
Fig. 2. Overall CGM ﬁndings. Left upper: octant conﬁguration in the maximum vector display; left lower: potential of ECG waves. Center: show three-dimensional loop
display: blue loop showing depolarization (R loop) with the green one, related to repolarization (T loop). Right: automatic interpretation and parameters. The analysis is done
automatically. If parameters are in green range they are normal but yellow and red areas are compatible with abnormal ﬁnding.
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in all electrocardiograms (e.g., ECG changes for myocardial
ischemia or prior myocardial infarction). These criteria were
deﬁned as horizontal or down-sloping ST depression 0.05 mV in
two contiguous leads; and/or T inversion 0.1 mV.
Serum level of magnesium, potassium and calcium were
determined at the day of ECG analysis in all psoriatic patients.Fig. 3. CGM maximum vectors. Hemisphere topography: 8 octants are displayed.
Apex located at the center, mid segments is around it and basal segments are
outside the hemisphere. Normally, the vectors of depolarization and depolarization
are at the standard area (green and blue area). Location and heterogeneity of R and T
vector (depolarization and depolarization) determine ischemia.
Please cite this article in press as: Poorzand H, et al. Cardiogoniomet
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All the statistical analyses were performed using the SPSS
statistical software (Statistical Package for Social Sciences,
version 16.0). Continuous variables were presented as mean-
s  standard deviation (SD). Normality tests (Kolmogorov–Smirnov
and Shapiro–Wilk) were used to assess the distribution pattern of
variables. T-test and chi-square test were used for analysis of
quantitative and qualitative variables, respectively. In case the data
were not normally distributed, non-parametric tests were used
for comparison. Pearson correlation analysis was used to assess
the correlation between variables. Level of signiﬁcance was set
at 0.05.
3. Results
Thirty psoriatic patients (40% (n: 12) female, the mean age of
45.43  12.42 years) and 30 healthy persons as control group (40% (n:
12) female, the mean age of 43.90  12.79 years) participated. Both
groups were matched by the age (p = 0.64) and the sex. Neither
psoriatic patients nor control group had risk factors for cardiovascular
diseases (including hypertension, hyperlipidaemia, diabetes mellitus,
cigarette smoking or family history of cardiovascular disease). All
psoriatic patients had normal sinus rhythm without ST-T changes.
ECG parameters (QT interval and dispersion) and CGM variables
(myocardial ischemia score and SDNN) were gathered in both groupsry in psoriatic patients and its comparison with a control group,
Table 1
ECG and CGM related variables in normal and patient group.
Variable Patient group N = 30 Control group N = 30 p value
QT interval 364.00  18.495 355.33  17.167 p = 0.065
QT corrected 392.64  26.00 377.26  22.34 p = 0.017
QT dispersion 32.00  17.88 6.67  15.162 p < 0.001
Heart rate 76.37  14.41 72.53  9.684 p = 0.02
SDNN 36.37  21.01 29.60  14.88 p = 0.29
Myocardial ischemia score 1.53  2.63 0.46  0.73 p = 0.037
All variables are given as mean  SD; SDNN: standard deviation of normal R-R
interval.
Fig. 5. Box-plots comparing the mean value of SDNN in the psoriatic patients and
the controls, the error bars have been superimposed.
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comparative bar charts (Figs. 4–6).
There was signiﬁcant difference between the psoriasis patients
and the controls in term of myocardial ischemia score
(1.53  2.63 vs 0.46  0.73, p = 0.037). Thirty three percent of
the controls had score <0 compared with 43% in the patient groups
but the ranges were 2.0 in the controls compared to 8.0 in the
patients (Figs. 6 and 7).
There was not signiﬁcant correlation between QT interval and
QT dispersion with PASI (r = 0.31, p = 0.873 and r = 0.213,
p = 0.259), or between QT interval and disease duration
(r = 0.051, p = 0.359). Moderate correlation was found between
QT dispersion and the disease duration (r = 0.369, p = 0.022).
Heart rate showed positive correlation with PASI (r = 0.427;
p = 0.009) but not with disease duration (p = 0.170; r = 0.180).
SDNN and myocardial ischemia score had positive correlation
with PASI (r = 0.427; p = 0.009, r = 0.481; p = 0.004) but not with
the disease duration (r = 0.124; p = 0.257; r = 0.233; p = 0.108).
4. Discussion
Cardiogoniometry is a non-invasive cardiovascular diagnostic
method, easy to use and inexpensive, providing automated
interpretation. It was assumed to be useful for early diagnosis of
ischemic heart disease especially in those patients who do not
tolerate exercise testing. Support vector machines have beenFig. 4. Bar charts comparing the mean value of corrected QT interval and QT disp
Please cite this article in press as: Poorzand H, et al. Cardiogoniomet
Indian Heart J. (2016), http://dx.doi.org/10.1016/j.ihj.2016.05.019applied in this technique to increase the diagnostic accuracy
(compared to the previous discriminant function analysis).
Resting ECG is not a precise screening method for detecting
myocardial ischemia in the primary setting. On the other hand,
exercise ECG often cannot be performed in all patients.11
Vector cardiography (VCG) has been proposed as an alternative
to the standard 12-lead ECG since the late 1930s.12
In VCG, spatial and temporal heterogeneity of the repolarization
phase (named as T-wave variability and T-wave alternance) have
been used for predicting ventricular tachyarrhythmia or sudden
cardiac death.
But it never became widely used in routine clinical practice due
to difﬁculty to interpret. On the other hand, coronary angiography
and nuclear imaging methods caused the classic VCG being
disappeared.
Cardiogonometry had been presented by Sanz et al. as an
alternative to classic VCG in ischemic heart disease diagnosis
(IHD).13 CGM is a vectorcardiographic method that is easier to
record than the conventional ECG (4 leads instead of 12), clearly
displays accurate three-dimensional surface electrophysiologicalersion in the patients and controls. The error bars have been superimposed.
ry in psoriatic patients and its comparison with a control group,
Fig. 6. Bar charts comparing the mean value of myocardial ischemia score in the patients and controls, the error bars have been superimposed.
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digitalized measurements. The variables used in the CGM score
serve to identify the abnormal spatial localization of cardiac
potentials and abnormal beat-to-beat variability. The use of these
variables is plausible since alterations of repolarization and
depolarization potentials are commonly used in the ECG diagnosis
of IHD.14,15
In a study on psoriatic patient without history of heart disease,
heart rate was signiﬁcantly higher (day and night) than the control
group using Holter monitoring. We did not use ECG Holter
monitoring in our study. The heart rate in ECG was higher
compared with the controls, showing positive correlation with
PASI but not with the disease duration.16
QT dispersion (QTd) can be used to assess the homogeneity of
cardiac repolarization and autonomic function denoting the
increased heterogeneity of repolarization could be associated with
increased risk of ventricular tachyarrhythmias.17,18
QT interval and QTD was higher in psoriatic patients, which
could be suggestive for increased risk of arrhythmia in such group
(like the study by Simsek at al). There was also positive correlation
between disease duration and QTD, which was moderate in our
study (r = 0.369; p = 0.022), compared with Simsek et al. study whoFig. 7. Distribution of myocardial ischemia scor
Please cite this article in press as: Poorzand H, et al. Cardiogoniomet
Indian Heart J. (2016), http://dx.doi.org/10.1016/j.ihj.2016.05.019found signiﬁcant relation (r = 0.693, p < 0.001). There were not
signiﬁcant correlations between PASI and QT dispersion.19
The data on rhythm disturbances or conduction abnormalities
are scarce. Increased sympathetic activity or systemic inﬂamma-
tion has been proposed as the mechanism of increased QT.20
We did not include the inﬂammatory markers in this study.
PASI score reﬂects the disease severity, thus it could also be
regarded as a useful measure of systemic inﬂammatory processes
intensity. Positive correlation was found between SDNN and PASI
but not with QT dispersion in our study. This might suggest the
inﬂammatory mechanism for increased heart rate variability in
such patients.
The association of psoriasis with comorbidities increasing the
risk of cardiovascular diseases was highlighted in many studies
and psoriasis was also found to be independently related with
myocardial infarction.21–23 Psoriasis has been associated with an
increased risk of atherosclerosis (e.g., ischemic heart disease and
stroke). The prevalence of such risk factors seems to increase from
mild to severe cases.24
In a meta-analysis, CGM was accurate in detecting 50%
coronary artery stenosis at rest with a sensitivity of 73% and a
speciﬁcity of 84%, respectively.25e in frequency in the patients and controls.
ry in psoriatic patients and its comparison with a control group,
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but similar speciﬁcity of for detecting CAD compared with ECG.26
In this study, there were no ST T changes in resting electrocar-
diogram but more negative values for myocardial ischemic score
were noted in CGM in psoriatic patients. The main concern was that a
conﬁrmatory test for coronary artery disease (CAD) was not done, so
the extent of atherosclerotic burden could not be evaluated and the
differences found in ischemia score could not be simply ascribed to
CAD. On the other hand, scores <0 was also detected in the controls
which raised the suspicion for generalized applicability of CGM for
myocardial ischemia detection in psoriasis.
After all, the abnormalities detected by CGM would raise
concerns about further cardiovascular follow-up in psoriatic
patients at least in those with severe disease. In other words, it
is prudent to deﬁne the risk of cardiovascular disease in psoriasis
and understand its determinants to propose the effective preven-
tion strategies.
5. Conclusion
Cardiogoniometry is a new, noninvasive, quantitative electro
diagnostic technique, which is helpful in identifying patients with
cardiovascular abnormalities and also predicting heart rate
variability. It can easily be performed at rest and provides an
accurate, automated diagnostic score. Abnormalities in resting ECG
and CGM and their positive relation with disease severity could
raise concerns about further cardiovascular follow-up in psoriatic
patients at least in those with severe disease. Whether increased
QTcD and abnormalities in CGM parameters in patients with
psoriasis predicts poorer clinical outcomes or mandates any
special treatments warrants further study.
5.1. Limitations
Small number of study patients and lack of long-term clinical
follow-up are the major limitations of our study. CT coronary
angiography or conventional angiography was not done. The extent
of atherosclerotic burden and the clinical importance of the
differences found in CGM data could not be deﬁned. Serum markers
of inﬂammation were not measured, so the exact pathophysiologic
mechanism of cardiovascular abnormalities could not be evaluated.
Automated ECG measurements were not available and manual
calculation QT measurements may be criticized.
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